Recently, immunologists have acquired great advances in harnessing immune checkpoint antibodies to block inhibitory receptors39, which suggested that KLRG1 might be the next target to prompt the cytotoxicity of KLRG1+CD8 T cells against tumor cells. Here, KLRG1 is linked to neoplasm.